Personalization in Gynecologic Oncology: Comprehensive Gynecology and Obstetrics
Editat de Masaki Mandaien Limba Engleză Hardback – 26 oct 2022
Personalization Gynecologic Oncology is a well-designed source for beginning to advanced oncologists, gynecologists, geneticists, genetic counselors, and nurses. Offering the latest treatment strategies, the Editor hopes the ideas presented here will be a foundation for further development in the field.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 511.98 lei 38-44 zile | |
Springer Nature Singapore – 27 oct 2023 | 511.98 lei 38-44 zile | |
Hardback (1) | 765.33 lei 22-36 zile | |
Springer Nature Singapore – 26 oct 2022 | 765.33 lei 22-36 zile |
Preț: 765.33 lei
Preț vechi: 805.61 lei
-5% Nou
Puncte Express: 1148
Preț estimativ în valută:
146.47€ • 152.59$ • 121.78£
146.47€ • 152.59$ • 121.78£
Carte disponibilă
Livrare economică 20 ianuarie-03 februarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789811947100
ISBN-10: 9811947104
Pagini: 147
Ilustrații: V, 147 p. 16 illus., 10 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.41 kg
Ediția:1st ed. 2022
Editura: Springer Nature Singapore
Colecția Springer
Seria Comprehensive Gynecology and Obstetrics
Locul publicării:Singapore, Singapore
ISBN-10: 9811947104
Pagini: 147
Ilustrații: V, 147 p. 16 illus., 10 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.41 kg
Ediția:1st ed. 2022
Editura: Springer Nature Singapore
Colecția Springer
Seria Comprehensive Gynecology and Obstetrics
Locul publicării:Singapore, Singapore
Cuprins
1 Personalized treatment in ovarian cancer.- 2 Carcinogenesis and personalization in hpv-associated precancer lesions of the cervix.- 3 Personalized treatment for gestational trophoblastic tumor.- 4 Personalized treatment in uterine sarcoma.- 5 Clinical relevance of brca1/2 pathogenic variants and impaired dna repair pathways in ovarian carcinomas.- 6 Personalized treatment in immunotherapy for gynecologic cancer.- 7 Risk assessment and prevention strategies for hereditary gynecological cancers.- 8 How genome-wide analysis contributes to personalized treatment in cancers including gynecologic cancers.- 9 Personalized treatment of gynecological cancer according to age and symptom benefit.
Notă biografică
Prof. Masaki Mandai, MD, PhD
Department of Gynecology and Obstetrics
Kyoto University Graduate School of Medicine
Department of Gynecology and Obstetrics
Kyoto University Graduate School of Medicine
Textul de pe ultima copertă
This book thoroughly illustrates the designed and tailored medical approaches for tumors of the female reproductive organ. The chapters explore different cancer species such as ovarian cancer, endometrial cancer, cervical cancer, etc. Various treatment modalities such as immunotherapy and histotype-specific treatment are delivered, and it offers a chapter on how genome-wide analysis contributes to personalized treatment. It is essential to understand this concept because many molecular target drugs and the prevalence of genome-based analysis in clinical settings have enabled us to introduce valid precision medicine in the field of gynecologic oncology. Chapters explain the stream of transition from conventional standardized treatment to personalized treatment and address future perspectives.
Personalization Gynecologic Oncology is a well-designed source for beginning to advanced oncologists, gynecologists, geneticists, genetic counselors, and nurses. Offering the latest treatment strategies, the Editor hopes the ideas presented here will be a foundation for further development in the field.
Personalization Gynecologic Oncology is a well-designed source for beginning to advanced oncologists, gynecologists, geneticists, genetic counselors, and nurses. Offering the latest treatment strategies, the Editor hopes the ideas presented here will be a foundation for further development in the field.
Caracteristici
Illustrates the designed and tailored medical approaches for tumors of the female reproductive organ Delivers various treatment modalities such as immunotherapy and histotype-specific treatment Explain the stream of transition from conventional standardized treatment to personalized treatment